Enzyme replacement therapy in porphyrias-IV. First successful human clinical trial of δ-aminolevulinate dehydratase-loaded erythrocyte ghosts

En:

Int. J. Biochem. 1983;15(10):1261-1265

Fecha:

1983

Formato:

application/pdf

Tipo de documento:

info:eu-repo/semantics/article
info:ar-repo/semantics/artículo
info:eu-repo/semantics/publishedVersion

Descriptores:

lead -  porphobilinogen synthase -  blood and hemopoietic system -  case report -  drug therapy -  drug toxicity -  enzyme therapy -  erythrocyte ghost -  human

Descripción:

1. 1. A patient with chronic lead intoxication was treated with only one course of highly purified human blood aminolaevulinate dehydratase entrapped in autologous erythrocyte ghosts given intravenously. 2. 2. No untoward effects were observed during or after infusion. 3. 3. An immediate increase in the patient's erythrocyte dehydratase activity was detected 1 hr after enzyme administration, reaching its maximum and nearly normal level 2 days later, values remained unchanged for a week, to slowly diminish after 2 weeks of initiated the treatment, and finally recovered activity was kept practically leveled off for weeks. 4. 4. This novel therapeutic trial produced complete improvement both clinical and biochemical, showing that enzyme infusion has been beneficial and can be safely and successfully used in the treatment of human lead intoxication. © 1983.
Fil:Del C. Batlle, A.M. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina.
Fil:Bustos, N.L. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina.
Fil:Stella, A.M. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina.

Identificador(es):

http://hdl.handle.net/20.500.12110/paper_0020711X_v15_n10_p1261_DelCBatlle

Derechos:

info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/2.5/ar